Xiaobin Wu Sells 626 Shares of BeOne Medicines (NASDAQ:ONC) Stock

BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) COO Xiaobin Wu sold 626 shares of BeOne Medicines stock in a transaction on Thursday, June 11th. The shares were sold at an average price of $261.20, for a total transaction of $163,511.20. Following the transaction, the chief operating officer owned 1,308,161 shares in the company, valued at approximately $341,691,653.20. This trade represents a 0.05% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Xiaobin Wu also recently made the following trade(s):

• On Monday, June 8th, Xiaobin Wu sold 1,484 shares of BeOne Medicines stock. The shares were sold at an average price of $269.37, for a total transaction of $399,745.08.

BeOne Medicines Stock Down 1.6%

ONC opened at $263.92 on Wednesday. The company has a debt-to-equity ratio of 0.20, a quick ratio of 3.27 and a current ratio of 3.64. BeOne Medicines Ltd. – Sponsored ADR has a fifty-two week low of $239.25 and a fifty-two week high of $385.22. The firm’s fifty day moving average is $297.63 and its 200 day moving average is $313.49. The stock has a market cap of $28.96 billion, a price-to-earnings ratio of 59.04 and a beta of 0.49.

BeOne Medicines (NASDAQ:ONC) last released its earnings results on Wednesday, April 1st. The company reported $0.25 earnings per share for the quarter. BeOne Medicines had a net margin of 8.94% and a return on equity of 12.06%. The company had revenue of $1.51 billion for the quarter. On average, sell-side analysts forecast that BeOne Medicines Ltd. – Sponsored ADR will post 6.14 earnings per share for the current fiscal year.

Institutional Trading of BeOne Medicines

A number of large investors have recently made changes to their positions in the business. Mariner LLC increased its holdings in shares of BeOne Medicines by 3.8% in the 4th quarter. Mariner LLC now owns 883 shares of the company’s stock worth $269,000 after buying an additional 32 shares during the last quarter. Signaturefd LLC increased its holdings in shares of BeOne Medicines by 10.7% in the 4th quarter. Signaturefd LLC now owns 340 shares of the company’s stock worth $103,000 after buying an additional 33 shares during the last quarter. Farther Finance Advisors LLC increased its holdings in shares of BeOne Medicines by 21.8% in the 4th quarter. Farther Finance Advisors LLC now owns 218 shares of the company’s stock worth $66,000 after buying an additional 39 shares during the last quarter. CWM LLC increased its holdings in shares of BeOne Medicines by 32.8% in the 4th quarter. CWM LLC now owns 158 shares of the company’s stock worth $48,000 after buying an additional 39 shares during the last quarter. Finally, Benjamin Edwards Inc. increased its holdings in shares of BeOne Medicines by 8.0% in the 4th quarter. Benjamin Edwards Inc. now owns 690 shares of the company’s stock worth $210,000 after buying an additional 51 shares during the last quarter. 48.55% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of analysts have issued reports on ONC shares. Morgan Stanley reiterated an “overweight” rating and issued a $395.00 price target on shares of BeOne Medicines in a report on Thursday, May 7th. Wells Fargo & Company started coverage on shares of BeOne Medicines in a report on Monday, May 4th. They issued an “overweight” rating and a $400.00 price target on the stock. Leerink Partners lifted their price target on shares of BeOne Medicines from $364.00 to $367.00 and gave the company an “outperform” rating in a report on Friday, May 15th. Zacks Research upgraded shares of BeOne Medicines from a “hold” rating to a “strong-buy” rating in a report on Thursday, June 4th. Finally, Guggenheim lifted their price target on shares of BeOne Medicines from $410.00 to $420.00 and gave the company a “buy” rating in a report on Thursday, May 7th. Two analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $390.00.

BeOne Medicines Company Profile

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.